Advanced Infusion Care Offers GC Biopharma’s ALYGLO™

AIC, a division within AIS Healthcare, has introduced a new treatment option for adults with primary humoral immunodeficiency (PI) through the availability of ALYGLO™, a product manufactured by GC Biopharma. This treatment is designed for conditions such as congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).

The inclusion of ALYGLO™ in AIC’s offerings marks a significant expansion in their range of immunoglobulin therapies. AIC’s nationally accredited home infusion teams work closely with healthcare providers to ensure that these specialized infusion services are delivered efficiently to patients either at home or in dedicated infusion centers. This collaboration facilitates a high level of personalized care tailored to meet the needs of PI patients.

Jud Hall, President of AIC, expressed enthusiasm about the new addition, stating that the partnership with GC Biopharma allows AIC to offer this extra-purified intravenous immunoglobulin (IVIg) therapy as an alternative for patients across the country. Stan Singley, Vice President of Trade & Procurement, echoed this sentiment, indicating that the company is pleased to expand its treatment portfolio.

In 2023, ALYGLO™ received approval from the U.S. Food and Drug Administration and is now accessible across all AIC locations, which include Valdosta, GA; Birmingham, AL; Panama City, FL; Cockeysville, MD; and Dallas, TX. Patients suffering from PI can expect comprehensive care from AIC, featuring round-the-clock access to clinical and support staff. A dedicated team of specialists, including clinical pharmacists, home infusion nurses, and patient access specialists, are assigned to support each patient throughout their treatment journey.

AIC distinguishes itself as more than just a specialty pharmacy by acting as a full-service care delivery partner. It maintains contracts with various immunoglobulin suppliers, including GC Biopharma, ensuring consistent availability of prescribed therapies. AIC engages directly with patients, insurance companies, and medical practitioners to streamline the process of securing necessary insurance authorizations and approvals.

AIS Healthcare, which holds accreditations from both URAC and the Accreditation Commission for Health Care (ACHC), stands out in the field of infusion services. This dual accreditation underscores its commitment to high standards and quality care.

For physicians interested in collaborating with AIC, they are encouraged to reach out to AIC representatives to begin the process. AIS Healthcare remains dedicated to advancing quality healthcare and improving patient lives. It leads the industry in providing infusion care solutions and targeted drug delivery, exceeding expectations in its service provision.

GC Biopharma, a company with a global presence in the biopharmaceutical sector, is the manufacturer of ALYGLO™. With a history dating back to 1971 when it produced its first plasma-derived therapy in South Korea, GC Biopharma has grown into one of the leading manufacturers of plasma therapeutics worldwide. The company distributes its products to over 50 countries and focuses on the development of innovative plasma-derived drugs. With one of the largest plasma manufacturing facilities globally, GC Biopharma continues its dedication to realizing its mission and vision of improving global health through pharmaceutical advancements.